Peripapillary Choroidal Thickness Change of Polypoidal Choroidal Vasculopathy after Anti-vascular Endothelial Growth Factor

Korean J Ophthalmol. 2017 Oct;31(5):431-438. doi: 10.3341/kjo.2016.0101.

Abstract

Purpose: To investigate the peripapillary choroidal thickness (PCT) of polypoidal choroidal vasculopathy (PCV) and exudative age-related macular degeneration (AMD) and to evaluate their responses to anti-vascular endothelial growth factor (VEGF).

Methods: Thirty eyes with PCV and 25 eyes with exudative AMD who were treatment naïve were included in this study. PCT and subfoveal choroidal thickness were evaluated both before and after intravitreal anti-VEGF.

Results: The initial mean PCT of PCV (153.78 ± 56.23 μm) was thicker than that of exudative AMD (88.77 ± 23.11 μm, p < 0.001). Temporal, superior, nasal, and inferior PCTs of PCV were all thicker than those observedin exudative AMD (all p < 0.05). After anti-VEGF, the mean PCT of PCV was significantly reduced (134.17 ± 41.66 μm, p < 0.001), but the same was not true not in exudative AMD (86.87 ± 22.54 μm, p = 0.392). PCTshowed a similar tendency in all quadrants.

Conclusions: PCV exhibits a thick choroid in the peripapillary region. PCT decreases after anti-VEGF in PCV but not in exudative AMD. In exudative AMD, subfoveal choroidal thickness decreased, but that in the peripapillary region did not.

Keywords: Anti-vascular endothelial growth factor; Choroid; Macular degeneration; Polypoidal choroidal vasculopathy.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Angiogenesis Inducing Agents / administration & dosage*
  • Bevacizumab / administration & dosage
  • Choroid / blood supply*
  • Choroid / pathology
  • Choroid Diseases / diagnosis*
  • Choroid Diseases / drug therapy
  • Female
  • Fluorescein Angiography
  • Follow-Up Studies
  • Fundus Oculi
  • Humans
  • Intravitreal Injections
  • Macula Lutea / pathology
  • Male
  • Middle Aged
  • Optic Disk / pathology*
  • Ranibizumab / administration & dosage
  • Retrospective Studies
  • Tomography, Optical Coherence
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*
  • Visual Acuity

Substances

  • Angiogenesis Inducing Agents
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • Ranibizumab